Scalper1 News
High-rated specialty-drug stock Horizon Pharma (HZNP) got an upgrade Tuesday in the wake of its deal to acquire an orphan-drug company. Piper Jaffray analyst David Amsellem lifted his rating to overweight from neutral and his price target to 31 from 21 on the strength of Horizon’s $1.1 billion buyout of Hyperion Therapeutics (HPTX). Amsellem singled out Hyperion’s drug Ravicti, a treatment for rare urea cycle disorders (UCD), calling it a “game Scalper1 News
Scalper1 News